Patterns of primary prophylactic granulocyte colony-stimulating factor use in older Medicare patients with cancer receiving myelosuppressive chemotherapy.
Jennifer R SchenfeldTingTing GongDavid HenryMichael KelshPrasad GawadeYi PengBrian D BradburyShuling LiPublished in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2022)
Despite cancer treatment guidelines recommending PP-G-CSF use to reduce risk of FN associated with HR and IR (with ≥ 1 patient risk-factor) regimens, PP-G-CSF remains underutilized in older patients, across cancer types and regimens. Opportunities exist for improvement in use of PP-G-CSF.